Integrated Investment Consultants LLC Boosts Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Integrated Investment Consultants LLC increased its Eli Lilly stake by 64.7% in the fourth quarter, buying 1,391 more shares and bringing its holdings to 3,541 shares valued at about $3.8 million.
• Wall Street remains broadly upbeat on Eli Lilly, with several firms raising price targets after strong results; the stock currently carries a Moderate Buy consensus and an average target price of $1,218.33.
• Eli Lilly reported blowout first-quarter earnings, with EPS of $8.55 and revenue of $19.8 billion, both well above estimates, and it raised its FY2026 EPS guidance to 35.5–37.0.

Integrated Investment Consultants LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 64.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,541 shares of the company's stock after acquiring an additional 1,391 shares during the quarter. Eli Lilly and Company accounts for about 0.8% of Integrated Investment Consultants LLC's portfolio, making the stock its 28th largest position. Integrated Investment Consultants LLC's holdings in Eli Lilly and Company were worth $3,805,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Brighton Jones LLC grew its stake in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after purchasing an additional 40 shares in the last quarter. Schnieders Capital Management LLC. grew its stake in shares of Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company's stock worth $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth $356,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth $749,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. HSBC downgraded shares of Eli Lilly and Company from a "hold" rating to a "reduce" rating and lowered their target price for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. TD Cowen boosted their target price on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a "buy" rating in a research note on Thursday, January 29th. Scotiabank reiterated an "outperform" rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,218.33.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Erste Group raised its FY2026 EPS estimate for Eli Lilly, lifting its forecast to $36.30 per share from $36.06 and above the broader consensus of $35.80, signaling continued earnings momentum.
• Positive Sentiment: Guggenheim recently boosted Lilly’s price target by $52 after the company’s strong first-quarter results, reinforcing the view that analysts see more upside after another blowout quarter.
• Positive Sentiment: Media coverage continues to highlight Lilly as one of the most watched stocks, with commentary pointing to its dominant position in the weight-loss drug market and ongoing bullish investor interest. Article: Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
• Positive Sentiment: Several reports pointed to Lilly’s expanding pipeline, including new and advancing trials in ALS, GI disease, and immuno-dermatology, which adds optionality beyond its core diabetes and obesity franchises.
• Positive Sentiment: Investor sentiment also got a boost from headlines calling Lilly a potential bull-market leader and suggesting the stock could approach $1,100 if momentum continues. Article: Is Eli Lilly Going To $1,100?
• Neutral Sentiment: Lilly and UNICEF announced a $50 million partnership tied to the company’s 150th anniversary, which may help its ESG profile and public image, but the direct earnings impact appears limited in the near term.
• Neutral Sentiment: Some articles were mainly awareness pieces or broad market commentary rather than company-specific catalysts, so they are unlikely to be major stock drivers on their own.
• Negative Sentiment: Broader market commentary warned that the S&P 500 may be due for a correction, which could create short-term pressure on high-multiple growth stocks like Lilly if risk appetite fades.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,005.20 on Monday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a market capitalization of $946.63 billion, a PE ratio of 35.71, a P/E/G ratio of 1.09 and a beta of 0.48. The company has a fifty day moving average of $939.88 and a two-hundred day moving average of $998.21.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the firm posted $3.34 earnings per share. Eli Lilly and Company's revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company's dividend payout ratio is currently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.